European Journal of Internal Medicine
Volume 21, Issue 2 , Pages 84-86 , April 2010

Cocaine and beta-blockers: The paradigm

Received 21 September 2009 ,Revised 24 November 2009 ,Accepted 25 November 2009.

References 

  1. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369:1047–1053
  2. Brody SL, Slovis CM, Wrenn KD. Cocaine-related medical problems: consecutive series of 233 patients. Am J Med. 1990;88:325–331
  3. Hollander JE, Hoffman RS, Gennis P, et al. Cocaine-associated chest pain: one-year follow-up. Acad Emerg Med. 1995;2:179–184
  4. Weber JE, Chudnofsky CR, Boczar M, Boyer EW, Wilkerson MD, Hollander JE. Cocaine-associated chest pain: how common is myocardial infarction?. Acad Emerg Med. 2000;7:873–877
  5. Lange RA, Cigarroa RG, Yancy CW, et al. Cocaine-induced coronary-artery vasoconstriction. N Engl J Med. 1989;321:1557–1562
  6. Afonso L, Mohammad T, Thatai D. Crack whips the heart: a review of the cardiovascular toxicity of cocaine. Am J Cardiol. 2007;100:1040–1043
  7. Moliterno DJ, Lange RA, Gerard RD, Willard JE, Lackner C, Hillis LD. Influence of intranasal cocaine on plasma constituents associated with endogenous thrombosis and thrombolysis. Am J Med. 1994;96:492–496
  8. Dressler FA, Malekzadeh S, Roberts WC. Quantitative analysis of amounts of coronary arterial narrowing in cocaine addicts. Am J Cardiol. 1990;65:303–308
  9. Om A, Ellahham S, DiSciascio G. Management of cocaine-induced cardiovascular complications. Am Heart J. 1993;125:469–475
  10. Wallace JE, Hamilton HE, King DE, Bason DJ, Schwertner HA, Harris SC. Gas–liquid chromatographic determination of cocaine and benzoylecgonine in urine. Anal Chem. 1976;48:34–38
  11. Linder MW, Bosse GM, Henderson MT, Midkiff G, Valdes R. Detection of cocaine metabolite in serum and urine: frequency and correlation with medical diagnosis. Clin Chim Acta. 2000;295:179–185
  12. Brogan WC, Lange RA, Kim AS, Moliterno DJ, Hillis LD. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin. J Am Coll Cardiol. 1991;18:581–586
  13. Rappolt RT, Gay GR, Inaba DS. Propranolol: a specific antagonist to cocaine. Clin Toxicol. 1977;10:265–271
  14. Rappolt RT, Gay G, Inaba DS, Rappolt NR. Propranolol in cocaine toxicity. Lancet. 1976;2:640–641
  15. Catravas JD, Waters IW. Acute cocaine intoxication in the conscious dog: studies on the mechanism of lethality. J Pharmacol Exp Ther. 1981;217:350–356
  16. Ramoska E, Sacchetti AD. Propranolol-induced hypertension in treatment of cocaine intoxication. Ann Emerg Med. 1985;14:1112–1113
  17. Sand IC, Brody SL, Wrenn KD, Slovis CM. Experience with esmolol for the treatment of cocaine-associated cardiovascular complications. Am J Emerg Med. 1991;9:161–163
  18. Kenny D, Pagel PS, Warltier DC. Attenuation of the systemic and coronary hemodynamic effects of cocaine in conscious dogs: propranolol versus labetalol. Basic Res Cardiol. 1992;87:465–477
  19. Boehrer JD, Moliterno DJ, Willard JE, Hillis LD, Lange RA. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med. 1993;94:608–610
  20. Sofuoglu M, Brown S, Babb DA, Pentel PR, Hatsukami DK. Effects of labetalol treatment on the physiological and subjective response to smoked cocaine. Pharmacol Biochem Behav. 2000;65:255–259
  21. Briggs RS, Birtwell AJ, Pohl JE. Hypertensive response to labetalol in phaeochromocytoma. Lancet. 1978;1:1045–1046
  22. Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther. 1992;14:292–305
  23. Frishman WH. Carvedilol. N Engl J Med. 1998;339:1759–1765
  24. Sofuoglu M, Brown S, Babb DA, Pentel PR, Hatsukami DK. Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug Alcohol Depend. 2000;60:69–76
  25. Rudoy CA, Van Bockstaele EJ. Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1119–1129
  26. Kelley BJ, Yeager KR, Pepper TH, Bornstein RA, Beversdorf DQ. The effect of propranolol on cognitive flexibility and memory in acute cocaine withdrawal. Neurocase. 2007;13:320–327
  27. Dattilo PB, Hailpern SM, Fearon K, Sohal D, Nordin C. Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use. Ann Emerg Med. 2008;51:117–125
  28. Missouris CG, Swift PA, Singer DR. Cocaine use and acute left ventricular dysfunction. Lancet. 2001;357:1586
  29. Blaho K, Winbery S, Park L, Gresham HW. Cocaine use and acute coronary syndromes. Lancet. 2001;358:1368
  30. Henning RJ, Li Y. Cocaine produces cardiac hypertrophy by protein kinase C dependent mechanisms. J Cardiovasc Pharmacol Ther. 2003;8:149–160
  31. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1–e157
  32. Page RL, Utz KJ, Wolfel EE. Should beta-blockers be used in the treatment of cocaine-associated acute coronary syndrome?. Ann Pharmacother. 2007;41:2008–2013

PII: S0953-6205(09)00241-6

doi: 10.1016/j.ejim.2009.11.010

European Journal of Internal Medicine
Volume 21, Issue 2 , Pages 84-86 , April 2010

Article Tools